Optometrist · New York, NY
NPI
1073584330
Since 2006
Specialty
Optometrist
Code 152W00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
4047 Broadway
New York, NY, 10032
Phone (212) 927-2020
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,163
192 services
Medicare patients, 2024
26
Average age 68
Drug cost, 2024
$3.2M
6,219 prescriptions
Company payments, 2025
$1,714
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Charles I Gold was code 76512 (ultrasound - nonspecific), 28 times for 14 patients. In total Charles I Gold billed 192 services in 15 codes, and Medicare paid $9,163.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-02-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 76512 Ultrasound - Nonspecific | Office | 28 | 14 | $39.29 | $1,100 |
| 92250 Angiography | Office | 23 | 23 | $29.91 | $688 |
| 92285 Standard X-ray | Office | 23 | 23 | $18.83 | $433 |
| 92020 Ophthalmological E&M | Office | 17 | 17 | $24.11 | $410 |
| 76514 Ultrasound - Nonspecific | Office | 17 | 17 | $9.55 | $162 |
| 92083 Vision, Hearing, and Speech Services | Office | 16 | 16 | $56.75 | $908 |
| 92014 Ophthalmological E&M | Office | 13 | 13 | $111.48 | $1,449 |
| 92286 Standard X-ray | Office | 13 | 13 | $31.75 | $413 |
| 92004 Ophthalmological E&M | Office | 12 | 12 | $131.56 | $1,579 |
Medicare prescription drug claims, 2024
In 2024, the drug Charles I Gold prescribed most often to Medicare patients was Xiidra (Lifitegrast), with 2,138 prescriptions and refills. In total Charles I Gold wrote 6,219 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xiidra Lifitegrast | 2,138 | 2,173 | 465 | $1.4M |
| Tyrvaya Varenicline Tartrate | 1,107 | 1,398 | 293 | $786K |
| Prolensa Bromfenac Sodium | 500 | 505 | 177 | $165K |
| Restasis Cyclosporine | 429 | 452 | 88 | $273K |
| Bromfenac Sodium Generic | 335 | 342 | 130 | $61K |
| Lumigan Bimatoprost | 279 | 549 | 71 | $153K |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 228 | 228 | 86 | $1,803 |
| Latanoprost Generic | 173 | 182 | 37 | $979 |
| Cequa Cyclosporine | 152 | 154 | 40 | $85K |
| Eysuvis Loteprednol Etabonate | 131 | 138 | 49 | $62K |
| Zerviate Cetirizine Hcl | 77 | 77 | 15 | $17K |
| Iyuzeh Latanoprost/Pf | 72 | 73 | 18 | $21K |
| Tobramycin-Dexamethasone Tobramycin/Dexamethasone | 70 | 75 | 28 | $3,846 |
| Alrex Loteprednol Etabonate | 62 | 80 | 16 | $28K |
| Azelastine Hcl Generic | 56 | 56 | 11 | $597 |
Brand drugs: 5,402 claims; generic drugs: 817 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Charles I Gold $1,714 ($1,714 in general payments such as food, travel and fees) from 9 companies. The largest payer was Alcon Vision LLC with $396.
| Company | Payments | Amount |
|---|---|---|
| Alcon Vision LLC ALC | 7 | $396 |
| Abbvie Inc. ABBV | 14 | $249 |
| Bausch & Lomb Americas Inc. BLCO | 6 | $223 |
| Harrow Eye, LLC | 10 | $210 |
| Oyster Point Pharma, Inc. | 7 | $163 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 8 | $157 |
| Tarsus Pharmaceuticals, Inc. TARS | 11 | $156 |
| Johnson & Johnson Vision Care, Inc. JNJ | 1 | $139 |
| Dompe US, Inc. | 1 | $21.18 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.